Back to search
FDAFDA · Food and drugs·Recall number Z-0604-2019

Binding Site Human IgM Kit (for SPAPLUS), REF: NK012.S The device consists of reaction buffer, sheep anti-IgM antiserum, six calibrators and two controls. The calibrators and controls are based on stabilized human serum. All components contain sodium azide as a preservative and are provided in ready-to-use liquid format.

Published December 19, 2018 · Recall initiated: November 6, 2018

Summary

FDA records medical device Class II recall Z-0604-2019, published December 19, 2018 and initiated November 6, 2018. Recalling firm: The Binding Site Group, Ltd.; Status: Terminated; Reported quantity: 60; Lot: Lot 413849. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Firm is offering advice to customers experiencing challenges when validating the calibration curve of the IgM kits. This is indicated by kit control values reporting outside the specified ranges.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
The Binding Site Group, Ltd.
Distributor
U.S Distribution to states of: CA, IL, PA, FL, NE, WA, IN, NY, SD and VA,
Lot
Lot 413849
Risk classification
Class II
Area (FDA)
device
Country
United Kingdom

Related recalls

Questions about this recall

Was Binding Site Human IgM Kit (for SPAPLUS), REF: NK012.S The device consists of reaction buffer, sheep anti-IgM antiserum, six calibrators and two controls. The calibrators and controls are based on stabilized human serum. All components contain sodium azide as a preservative and are provided in ready-to-use liquid format. recalled?

Yes. FDA published recall Z-0604-2019 on December 19, 2018. Reported hazard: Firm is offering advice to customers experiencing challenges when validating the calibration curve of the IgM kits. This is indicated by kit control values reporting outside the specified ranges.

What should I do if I have this product?

Voluntary: Firm initiated · Letter